Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain.
Ubiquitylation and Cancer Molecular Biology laboratory, Inbiomed, San Sebastian-Donostia, Gipuzkoa, Spain.
Oncogene. 2015 Mar 12;34(11):1442-50. doi: 10.1038/onc.2014.48. Epub 2014 Apr 7.
Serine threonine kinase AKT has a central role in the cell, controlling survival, proliferation, metabolism and angiogenesis. Deregulation of its activity underlies a wide range of pathological situations, including cancer. Here we show that AKT is post-translationally modified by the small ubiquitin-like modifier (SUMO) protein. Interestingly, neither SUMO conjugation nor activation of SUMOylated AKT is regulated by the classical AKT targeting to the cell membrane or by the phosphoinositide 3-kinase pathway. We demonstrate that SUMO induces the activation of AKT, whereas, conversely, down-modulation of the SUMO machinery diminishes AKT activation and cell proliferation. Furthermore, an AKT SUMOylation mutant shows reduced activation, and decreased anti-apoptotic and pro-tumoral activities in comparison with the wild-type protein. These results identify SUMO as a novel key regulator of AKT phosphorylation and activity.
丝氨酸苏氨酸激酶 AKT 在细胞中具有核心作用,控制着细胞的存活、增殖、代谢和血管生成。其活性的失调是广泛病理情况的基础,包括癌症。在这里,我们表明 AKT 被小分子泛素样修饰物(SUMO)蛋白进行翻译后的修饰。有趣的是,SUMO 的缀合以及 SUMO 化 AKT 的激活既不受经典的 AKT 靶向细胞膜调控,也不受磷酸肌醇 3-激酶途径调控。我们证明 SUMO 诱导 AKT 的激活,相反,SUMO 机制的下调会减少 AKT 的激活和细胞增殖。此外,与野生型蛋白相比,AKT SUMO 化突变体的激活减少,抗凋亡和促肿瘤活性降低。这些结果表明 SUMO 是 AKT 磷酸化和活性的一个新的关键调控因子。